Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 162.97M P/E - EPS this Y -22.30% Ern Qtrly Grth -
Income -46.05M Forward P/E -7.40 EPS next Y 67.30% 50D Avg Chg -7.00%
Sales 27.46M PEG - EPS past 5Y - 200D Avg Chg -7.00%
Dividend N/A Price/Book 2.28 EPS next 5Y - 52W High Chg -30.00%
Recommedations 1.80 Quick Ratio 1.16 Shares Outstanding 41.85M 52W Low Chg 19.00%
Insider Own 8.08% ROA -21.55% Shares Float 36.09M Beta 1.84
Inst Own 29.76% ROE -67.23% Shares Shorted/Prior 2.37M/2.13M Price 4.81
Gross Margin 89.28% Profit Margin -167.69% Avg. Volume 279,700 Target Price 19.00
Oper. Margin -111.00% Earnings Date May 13 Volume 112,464 Change -1.84%
About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Zevra Therapeutics, Inc. News
04/29/24 Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
04/15/24 Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
04/10/24 Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
04/04/24 Zevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
04/03/24 Bearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimates
04/01/24 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
03/31/24 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported, And Analysts Assigned A US$18.25 Price Target
03/29/24 Q4 2023 Zevra Therapeutics Inc Earnings Call
03/28/24 Zevra Therapeutics Inc (ZVRA) Earnings: A Mixed Bag Against Analyst Estimates with Significant ...
03/28/24 Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
03/26/24 Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
03/25/24 Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
03/21/24 Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know
03/18/24 Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
03/14/24 Zevra Therapeutics (NASDAQ:ZVRA) investors are sitting on a loss of 81% if they invested five years ago
03/04/24 Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
02/28/24 Zevra Therapeutics to Participate at Upcoming Investor Conferences
02/15/24 Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
02/06/24 Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
02/01/24 Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
ZVRA Chatroom

User Image yodog941 Posted - 21 minutes ago

$ZVRA I guess I need to submit sell order for $10 and to get there before eoy. So tired from this shit show

User Image WaynD01 Posted - 46 minutes ago

$ZVRA How outrageous the compensation for a CEO of a tiny company can be!! The 700,000 RSU is on top of all these. Is this the governance you are trying to establish at the company as you said in the letters to shareholder?!!

User Image WaynD01 Posted - 56 minutes ago

$ZVRA Any one has link or screen shot of the ISS and Glass Lewis recommendations? I have heard they are seeing multiple issues with the Incentive proposal. @Tiptoe123 @M_OF_E

User Image pmcgee5029 Posted - 2 hours ago

$ZVRA We've been in this channel for over 2 years, now! All the while producing excellent products and providing excellent news! Patience, Retirement Year 2038!

User Image IowaInvest11 Posted - 2 hours ago

$ZVRA $QQQ $SPY Below is pry the best thing we need implemented in our government. Just like when a company like Zevra is not working in our best investor interests, we can hold it to a vote for change. The same thing applies in Switzerland where the majority can make change happen quickly and not get slowed down by politicians getting nothing done like the border. It will come to a nationwide referendum in Switzerland

User Image Treyjones6568 Posted - 3 hours ago

$ZVRA well with very little trading volume it gives me hope we are coming to a reversal here soon and lots of volume soon. Soon being a relative term. Could be early June unless for some crazy unknown reason management drops some good PR

User Image Regan_Proxy Posted - 4 hours ago

$ZVRA NOT enjoying ... being held back.

User Image Adamek45 Posted - 4 hours ago

$ZVRA isn't anyone else pissed at what us long timers have had to deal with????

User Image Regan_Proxy Posted - 4 hours ago

@gc358 @ReggieWhit2 As a $ZVRA shareholder, I voted "Withhold Authority" on the 3 nominees and "Against" the other 3 proposals. I accept the fact that some (large) shareholders (here) know MORE THAN me ... regarding what is currently happening behind-the-curtain. IF it was up to ME, I'd be fighting management ... right NOW!

User Image Synergy1 Posted - 4 hours ago

$ZVRA these loser can’t bring us value if it meant their lives 🙄

User Image Adamek45 Posted - 4 hours ago

$ZVRA why aren't we climbing faster? I mean, seriously. They are doing hard work to keep us down aren't they?!

User Image EthanStawk Posted - 5 hours ago

$ZVRA Oh, fuck, y'all, I just got Boiler Roomed by spartan capital. I guess all the expansion of my business and net worth got me on a list, but dude got on the wrong phone call. Wanted to sell me Microsoft, because it was going to $550 in 90 days. "So, you're telling me Microsoft is going to add 1.5 trillion dollars to their market cap in 90 days?" Backpedaling because of course. Then, being a guy who started out as a telemarketer... I leaned into Zevra. He called me a gambler. I asked if he thought 3 years of research constituted gambling, because there are professional gamblers who live off their research. Eventually homie got tired. It was an absolute riot. Pretty sure Christopher Moltisanti was in the background.

User Image jemer Posted - 6 hours ago

$ZVRA Reading that Pediactric Rare disease voucher program ends Sept 30, 2024. Congress has proposed a bill; HR 7384, that extends the voucher program by 5 years. I assume that a PDFUA approval for Arimoclomol on or before 9/21/2024, gets ZVRA the voucher before end of September. I also assume that voucher program will be extended for 5 years.

User Image sirloud13 Posted - 7 hours ago

$ZVRA decided to listen to @skywrangler bought some Friday. Time to go to $6-7.

User Image Skovo Posted - 7 hours ago

$ZVRA ironically this is the gain leader on my whole ticker watchlist lol…

User Image KemPharm_rocks Posted - 7 hours ago

$ZVRA I wonder how Travis feels, knowing that he’s the only one attached to Zevra, where the bulk of his shares are tied to PERFORMANCE (i.e., FDA passing Arimoclomol).

User Image pmcgee5029 Posted - 7 hours ago

$ZVRA Purchased more, yesterday and I will continue purchasing more as long as the SP still at these prices!

User Image xconnor759 Posted - 7 hours ago

$ZVRA Id vote differently if we wernt down 15% from a year ago

User Image ReggieWhit2 Posted - 8 hours ago

$ZVRA Folks, I spouted off yesterday and expressed my frustration with the proposal to use 6 million shares for “equity participation”. I do understand the need for and the history of granting stock to key employees. Understandable. But what are the performance standards? Especially in granting the RSU’s? No accountability. And with approx. 41 million shares outstanding, an additional 6 million is dilutive. And with the acquisition of these companies, I and you know there is extra baggage. Mr. McFarlane received a hefty number of shares previously, with no strings attached. How about insiders stepping up and buying their stock? But I know…..why should they? Anyway, I already voted no because of the timing of this proposal and its structure, especially considering the common shareholders’ continued plight and total dismissal by management.

User Image CooperHandy Posted - 8 hours ago

$ZVRA They added an EIAP of 1.5m shares last year that did NOT require shareholder approval which they've since increased to 4.5m shares. "In February 2024, our Board approved the Amended and Restated 2023 Employment Inducement Award Plan, (the “2023 Plan”), under which we may grant equity awards to certain new employees. The maximum number of shares of common stock to be issued under the 2023 Plan is 4,500,000." They still have an auto increase to the EIP of 4% annually which at ~40m OS equates to ~1.6m shares being added and gives them ~3m shares under the current EIP. They still have the ESPP with 1.4m shares available. Yet they have the audacity to ask for 6m more shares for the EIP after a burn rate of ~15% and their egregious awards to people like LD, Neil and Adrian for either lackluster performance or no performance at all yet. Simple fix Neil... go back to a burn rate of 4% and you'll never run out of shares in the EIP 😏😉🤓

User Image smp321 Posted - 8 hours ago

$ZVRA with Glass and ISS comments; I'd be beyond surprised if the comp passes! With that said, its also a "mark" against this management team and my concern is what will institutional investors think? At the end of the day, if Acer's drug sells and we get the FDA node, it will not matter. If there is an opportunity for these institutions to make money... they will regardless of who is at the helm.

User Image sirloud13 Posted - 9 hours ago

$ZVRA

User Image Seeking10x Posted - 9 hours ago

$ZVRA most unethical bored I’ve ever seen hands down. I would never feel comfortable taking the kinds of rewards they’ve given themselves while continually delivering NOTHING!! to shareholders. 🐶 💩 humans!

User Image RaySan Posted - 10 hours ago

$ZVRA Our current status is bad enough but if this ever makes us any money inflation will negate it's worth. FJB and everyone who voted for him.

User Image Adamek45 Posted - 10 hours ago

$ZVRA this new team has done NOTHING BUT LOSE US MONEY. Updates are horrific and no azstarys weekly updates. No arimoclomol backing either. I am beyond pissed at this could-have-been. I am forced to wait it out still.

User Image Bayrider Posted - 10 hours ago

$ZVRA Neil could have saved himself a bunch of time, in writing his letter, had he just given the shareholders the middle finger. A picture is worth a thousand words.

User Image BMW2002 Posted - 10 hours ago

$ZVRA

User Image Adamek45 Posted - 10 hours ago

$ZVRA cmon already. I've waited long enough for this to get back to azstarys approval price. Cmon.

User Image Dr_Bearfvcker Posted - 11 hours ago

$ZVRA And for the person that was wondering how these scummy BIO CEO's keep getting high paying jobs.....Neil and Pascoe have shown you exactly how. They get insiders paid. Thats it. Thats all it takes. Nobody gives a fuck about performance. How much can you get us? Thats the interview question.

User Image SAW62 Posted - 11 hours ago

$ZVRA I can see the BOD’s being rewarded when they bring rewards to the shareholders. Ive been stuck in this crap for 7 years and I have seen these greedy bastards just take the shares for themselves. Vote No. I cant wait to get the hell away from this pathetic company.

Analyst Ratings
HC Wainwright & Co. Buy Apr 3, 24
Cantor Fitzgerald Overweight Apr 1, 24
William Blair Outperform Mar 12, 24
HC Wainwright & Co. Buy Mar 5, 24
HC Wainwright & Co. Buy Dec 28, 23
Roth MKM Buy Oct 6, 23
Canaccord Genuity Buy Sep 1, 23
Canaccord Genuity Buy Aug 15, 23
Maxim Group Buy Mar 17, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schafer Joshua CCO & EVP, Bus. Deve.. CCO & EVP, Bus. Development Sep 05 Buy 5.129 500 2,564 3,500 09/06/23
Clifton R. LaDuane CFO, Secretary & Tre.. CFO, Secretary & Treasurer Sep 06 Buy 4.9591 1,000 4,959 15,309 09/06/23
Schafer Joshua CCO & EVP, Bus. Deve.. CCO & EVP, Bus. Development May 19 Buy 5.4157 1,000 5,416 3,000 06/30/23
Watton Corey Michael Director Director Jun 09 Buy 5.52 325 1,794 725 06/13/23
Watton Corey Michael Director Director May 30 Buy 5.1053 400 2,042 400 05/31/23
Clifton R. LaDuane CFO, Secretary & Tre.. CFO, Secretary & Treasurer May 18 Buy 4.95 2,740 13,563 13,742 05/18/23
Schafer Joshua CCO & EVP, Bus. Deve.. CCO & EVP, Bus. Development Mar 14 Buy 4.6089 2,000 9,218 2,000 03/15/23
Plooster Matthew R Director Director Mar 09 Buy 4.19530 11,000 46,148 18,500 03/13/23
Sangiovanni Timothy J. SVP, Corporate Contr.. SVP, Corporate Controller Mar 10 Buy 4.14 1,200 4,968 4,449 03/13/23
Clifton R. LaDuane CFO, Secretary & Tre.. CFO, Secretary & Treasurer Mar 10 Buy 4.15 1,725 7,159 11,002 03/13/23
Tierney David S Director Director Mar 09 Buy 4.1463 5,000 20,732 10,835 03/13/23
Pascoe Richard W Chief Executive Offi.. Chief Executive Officer Mar 09 Buy 4.19780 10,000 41,978 29,973 03/13/23
Clifton R. LaDuane CFO, Secretary & Tre.. CFO, Secretary & Treasurer Jan 13 Buy 5.7 635 3,620 9,277 01/13/23
Pascoe Richard W Chief Executive Offi.. Chief Executive Officer Jan 13 Buy 5.4399 9,500 51,679 19,973 01/13/23
Tierney David S Director Director May 25 Buy 4.39 2,000 8,780 5,835 05/26/22
Mickle Travis C President & CEO President & CEO May 25 Buy 4.38 13,000 56,940 11,034 05/25/22
SEYMOUR TAMARA A Director Director May 20 Buy 4.87 200 974 200 05/24/22
Plooster Matthew R Director Director May 18 Buy 4.96 5,000 24,800 7,500 05/18/22
Pascoe Richard W Executive Chairman Executive Chairman May 18 Buy 4.92 5,000 24,600 8,285 05/18/22
Clifton R. LaDuane CFO, Secretary & Tre.. CFO, Secretary & Treasurer May 18 Buy 4.9992 1,200 5,999 6,440 05/18/22